Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A banner appears announcing NIH website transition updates and FAQs, with a notice that federal agencies are using “Super Intelligence” instead of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T13:44:06.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-17T14:31:48.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T14:38:51.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The study details page now displays a 403 Forbidden error in place of the content. This indicates an access restriction and prevents viewing the study record and page navigation as before.
    Difference
    0.5%
    Check dated 2026-09-26T16:28:27.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error, replacing the study record content and making the trial information inaccessible to users.
    Difference
    18%
    Check dated 2026-09-19T18:31:02.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.5 to v3.6.6, indicating a new release version. This update is an internal version change and does not modify the study content.
    Difference
    0.1%
    Check dated 2026-08-29T21:50:34.000Z thumbnail image

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.